超中央型肺肿瘤的立体定向消融放疗:优先靶区覆盖还是危及器官?
结果显示优先靶区覆盖时50 Gy/5次和60 Gy/8次肿瘤控制概率约92%,但≥4级近端支气管树毒性风险分别达68%和44%;优先危及器官时毒性降低但控制概率下降。结论认为60 Gy/8次在适当妥协靶区覆盖时可能取得最佳平衡。
要点
- 超中央型肺肿瘤SABR需权衡局部控制与中央气道毒性。
- 优先靶区覆盖时50 Gy/5次和60 Gy/8次的≥4级支气管树毒性风险高。
- 60 Gy/8次适当妥协靶区覆盖可能取得最佳平衡。
核心结论
- 超中央型肺癌常用大分割放疗方案在局部控制与中央气道毒性之间存在显著权衡。
- 计划研究预测60 Gy/8次在按需妥协PTV覆盖以维持OAR可接受剂量时可能取得最佳平衡。
研究设计与样本
- 为50 Gy/5次、60 Gy/8次和60 Gy/15次三种大分割方案分别生成优先PTV覆盖和优先OAR约束的两套计划。
- 采用已发表的放射生物学模型评估局部控制概率和OAR毒性风险。
主要发现
- 所有场景下食管或肺毒性风险均低于5%。
- 优先PTV覆盖时,肿瘤控制概率分别为50 Gy/5次92.9%、60 Gy/8次92.4%、60 Gy/15次52.0%。
- 优先PTV覆盖时,近端支气管树≥4级毒性估计风险分别为68%、44%和2%。
- 优先OAR剂量时,所有方案主要肺毒性风险降至<1%,但肿瘤控制概率分别降至60.3%、65.7%和47.8%。
临床怎么用
- 超中央型肺肿瘤SABR应个体化权衡靶区覆盖与OAR约束。
- 60 Gy/8次可在必要时妥协PTV覆盖以维持OAR可接受剂量。
局限性
- 结果基于放射生物学模型预测,需前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung stereotactic ablative radiotherapy (SABR) is associated with low morbidity, however there is an increased risk of treatment-related toxicity in tumors directly abutting or invading the proximal bronchial tree, termed 'ultra-central' tumors. As there is no consensus regarding the optimal radiotherapy treatment regimen for these tumors, we performed a modeling study to evaluate the trade-offs between predicted toxicity and local control for commonly used high-precision dose-fractionation regimens. METHODS: Ten patients with ultra-central lung tumors were identified from our institutional database. New plans were generated for 3 different hypofractionated schemes: 50 Gy in 5 fractions, 60 Gy in 8 fractions and 60 Gy in 15 fractions. For each regimen, one plan was created that prioritized planning target volume (PTV) coverage, potentially at the expense of organ at risk (OAR) tolerance, and a second that compromised PTV coverage to respect OAR dose constraints. Published radiobiological models were employed to evaluate competing treatment plans based on estimates for local control and the likelihood for toxicity to OAR. RESULTS: The risk of esophageal or pulmonary toxicity was low (< 5%) in all scenarios. When PTV coverage was prioritized, tumor control probabilities were 92.9% for 50 Gy in 5 fractions, 92.4% for 60 Gy in 8 fractions, and 52.0% for 60 Gy in 15 fractions; however the estimated risk of grade ≥ 4 toxicity to the proximal bronchial tree was 68%, 44% and 2% respectively. When dose to OAR was prioritized, the risk of major pulmonary toxicity was reduced to < 1% in all schemes, but this compromise reduced tumor control probability to 60.3% for 50 Gy in 5 fractions, 65.7% for 60 Gy in 8 fractions and 47.8% for 60 Gy in 15 fractions. CONCLUSIONS: The tradeoff between local control and central airway toxicity are considerable in the use of 3 commonly used hypofractionated radiotherapy regimens for ultra-central lung cancer. The results of this planning study predict that the best balance may be achieved with 60 Gy in 8 fractions compromising PTV coverage as required to maintain acceptable doses to OAR. A prospective phase I trial (SUNSET) is planned to further evaluate this challenging clinical scenario.
引用
- Murrell DH, Laba JM, Erickson A, et al. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk? Radiat Oncol. 2018. PMID: 29606150. doi:10.1186/s13014-018-1001-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。